Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.
Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.
Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.
Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.
Proteostasis (PTI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.
What in Store for Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
What's in Store for Tenet Healthcare's (THC) Q4 Earnings?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 results are likely to reflect higher revenues, aided by its Hospital and Other Operations as well as Ambulatory segments, partly offset by lower admissions.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.
bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.
What's in Store for Select Medical's (SEM) Q4 Earnings?
by Zacks Equity Research
Select Medical's (SEM) Q4 results are likely to reflect revenue growth across all its segments, increase in expenses and share buyback.
Deere (DE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Deere's (DE) Q1 results likely to reflect benefits from advanced technologies, precision agriculture and cost management despite a choppy agricultural sector.
Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -13.04% and 5.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.